Healthcare [ 5/13 ] | Biotechnology [ 49/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0 Increased by +100% | -0.17 Increased by +100% |
| Mar 27, 24 | 0 Increased by +100% | -0.16 Increased by +100% |
| Nov 14, 23 | -0.28 Decreased by -27.27% | -0.2 Decreased by -40% |
| Aug 10, 23 | -0.21 Increased by +12.5% | -0.21 |
| May 11, 23 | -0.21 Increased by +12.5% | -0.21 |
| Mar 24, 23 | -0.28 Increased by +54.84% | -0.23 Decreased by -21.74% |
| Nov 10, 22 | -0.22 Decreased by -4.76% | -0.23 Increased by +4.35% |
| Aug 15, 22 | -0.24 Increased by +35.14% | -0.23 Decreased by -4.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 87 K Increased by +262.5% | 44.24 M Increased by +232.99% | Increased by +50.86 K% Increased by +136.69% |
| Jun 30, 23 | 172 K Increased by +1.18% | -33.04 M Decreased by -7.08% | Decreased by -19.21 K% Decreased by -5.84% |
| Mar 31, 23 | 37 K Increased by +N/A% | -33.32 M Decreased by -4.25% | Decreased by -90.06 K% Decreased by N/A% |
| Dec 31, 22 | 38 K Decreased by -83.48% | -45.32 M Increased by +49% | Decreased by -119.27 K% Decreased by -208.66% |
| Sep 30, 22 | 24 K Decreased by -90.98% | -33.27 M Decreased by -6.78% | Decreased by -138.62 K% Decreased by -1.08 K% |
| Jun 30, 22 | 170 K Increased by +N/A% | -30.86 M Increased by +36.33% | Decreased by -18.15 K% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by -100% | -31.96 M Decreased by -4.75 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 230 K Increased by +N/A% | -88.88 M Decreased by -2.64% | Decreased by -38.64 K% Decreased by N/A% |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.